# US 10,765,742 B2 · Methods of treating CD166-expressing cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,742 B2
- Document ID: US10765742B2
- Status: Granted
- Kind: B2
- Application number: 15/745,582
- Filed: 2016-07-18
- Published: 2018-07-26
- Granted: 2020-09-08
- Earliest claimed: 2015-07-17
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: Nicole Suciu-Foca; George Vlad; Zheng Xu
- Inventors: Nicole Suciu-Foca; George Vlad; Zheng Xu
- Web page: https://patentgrep.com/patent/US10765742B2

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.

## Claims

### Claim 1

A method comprising administering to a subject having a CD166-expressing cancer a therapeutically effective amount of an agent selected from the group consisting of full length ILT3, the extracellular domain of ILT3 and LT3Fc thereby treating the cancer, wherein the agent inhibits the interaction between ILT3 expressed on monocytes, macrophages, and dendritic cells with CD166 expressed on cancer cells, and the therapeutically effective amount significantly reduces the proliferation of the CD166-expressing cancer cells compared to respective pretreatment levels or significantly increases apoptosis of the CD166-expressing cancer cells compared to a pretreatment level.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CD166-expressing cancer is selected from the group consisting of leukemia, lymphoma, prostate, breast, lung, kidney, pancreas, and melanoma cancers.

### Claim 3 (depends on 2)

The method of claim 2, wherein the leukemia is chronic myelogenous leukemia (AML), Acute B cell leukemia line or adult T-cell leukemia (T-ALL), and the lymphoma is cutaneous T cell lymphoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent is administered systemically or locally to the CD166-expressing cancer.